MYC and medulloblastoma: The observation that the SHH‐TP53‐mutated cell line—Daoy—is less susceptible to lower doses of Axitinib might also reflect the fact that Daoy differs in its target profile from the myc‐amplified medulloblastoma lines MEB‐Med‐8A and D283 Med with similar VEGFR1‐3, PDGFR α/β receptor but lower levels of c‐kit receptor expression (Table S1).